Pharmacotherapy of Neuropathic Pain: Time To Rewrite The Rulebook?

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

NB Finnerup receives research funding from the EUROPAIN project funded by the Investigational Medicines Initiative, a public–private partnership between the EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA). N Attal received honoraria from Pfizer, Lilly, Grunenthal, Adir, Astellas, Johnson and Johnson, Sanofi Pasteur Mérieux, Astra Zeneca for participation in clinical trials, advisory boards or speakers bureau. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

NB Finnerup receives research funding from the EUROPAIN project funded by the Investigational Medicines Initiative, a public–private partnership between the EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA). N Attal received honoraria from Pfizer, Lilly, Grunenthal, Adir, Astellas, Johnson and Johnson, Sanofi Pasteur Mérieux, Astra Zeneca for participation in clinical trials, advisory boards or speakers bureau. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.